Feng TianBS, PhD
Feng Tian, Ph. D. has held increasing roles of responsibility at Ambrx since joining the company in 2004. Currently, as Chief Scientific Officer, Dr. Tian oversees the company’s research and development. During his tenure at Ambrx, Dr. Tian has been instrumental in the establishment and improvement of Ambrx technology and product platforms. He played a key role in the establishment of the EuCODE technology platform (site-specific non-natural amino acid incorporation in eukaryotic cells); he led teams to establish Ambrx site-specific antibody drug conjugate (ADC) technology platform, and the ADC pipeline and “Switch” vaccine platform. More recently, on the business side, Dr. Tian initiated and established the Ambrx China Strategy. He is playing a central role in building China collaborations, and most recently, in the Ambrx M&A process. Prior to joining Ambrx, Dr. Tian conducted his postdoctoral study at The Scripps Research Institute where his work involved catalytic antibodies, non-natural amino acid incorporation and biosensors. Dr. Tian received his Ph. D. in Chemistry from the University of Florida with a dissertation in the field of physical organic chemistry and received his B. S. in Chemistry from Peking University.